Efficacy of Preventing Relapse Evaluated by a Multicenter Randomized Double-Blind Placebo-Controlled Withdrawal Study of Escitalopram in Japanese Adolescents with Major Depressive Disorder
Journal of Child and Adolescent Psychopharmacology · 2023-12 · 33 (10) · 418-427
DOI: 10.1089/cap.2023.0048 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Child and Adolescent Psychopharmacology, online erschienen am 15.12.2023. Verfasst von Takuya Saito und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Child and Adolescent Psychiatry, Hokkaido University Hospital, Sapporo, Japan. Hauptthemen laut MEDLINE: Major Depressive Disorder. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To evaluate the efficacy and safety of escitalopram (ESC) in a 48-week relapse prevention study in Japanese adolescents with major depressive disorder (MDD).
Methods
This was a 48-week multicenter randomized double-blind placebo-controlled parallel-group study of patients aged 12–17 years with MDD. Patients received ESC for 12 weeks as an open-label treatment period (open-label period). Patients who achieved criteria for remission or response in the open-label period received either ESC or placebo for 36 weeks as a double-blind treatment period (double-blind period). The primary endpoint was the time to relapse during the double-blind period. Safety was evaluated in terms of type, incidence, and severity of adverse events.
Results
Of the 128 patients who entered the open-label period, 80 patients entered the double-blind period, all of whom were in the primary analysis population. The primary endpoint, time to relapse, was marginally less than statistically significant between the ESC and placebo groups ( p = 0.051, log-rank test). In the Cox proportional hazards model, the estimated hazard ratio [two-sided 95% confidence interval] for relapse in the placebo group versus the ESC group was 2.96 [0.94, 9.30]. There were statistically significant differences between the ESC and placebo groups in several secondary endpoints (change in Children's Depression Rating Scale-Revised, change in Clinical Global Impressions-Severity Scale, etc.). No notable safety/tolerability issues were observed in this study compared with the results of studies in Japanese adults with MDD.
Conclusions
Superiority of ESC over placebo for relapse prevention in Japanese adolescents aged 12–17 years with MDD could not be verified with time to relapse evaluated by log-rank test. However, secondary endpoint results and a post hoc analysis of time to relapse suggest that ESC may be effective in preventing MDD relapse. No notable safety/tolerability issues were observed compared with the results of studies in Japanese adults with MDD. Study Registry Number: jRCT2080224520
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Child and Adolescent Psychiatry, Hokkaido University Hospital, Sapporo, Japan.
- Kochi Medical School Department of Child and Adolescent Psychiatry, Kochi University, Kochi, Japan.
- Department of Child Mental Health and Development, Toyama University Hospital, Toyama, Japan.
- Department of Child Psychiatry, Chiba University Hospital, Chiba, Japan.
- Mochida Pharmaceutical Co., LTD., Shinjuku-ku, Japan.
ORCID-Profile: Masaki Sato
Zitieren
APA
Saito, T., Takahashi, H., Tsujii, N., Sasaki, T., Yamaguchi, Y., Takatsu, M., & Sato, M. (2023). Efficacy of Preventing Relapse Evaluated by a Multicenter Randomized Double-Blind Placebo-Controlled Withdrawal Study of Escitalopram in Japanese Adolescents with Major Depressive Disorder. Journal of Child and Adolescent Psychopharmacology, 33(10), 418-427. https://doi.org/10.1089/cap.2023.0048
Vancouver
Saito T, Takahashi H, Tsujii N, Sasaki T, Yamaguchi Y, Takatsu M, et al. Efficacy of Preventing Relapse Evaluated by a Multicenter Randomized Double-Blind Placebo-Controlled Withdrawal Study of Escitalopram in Japanese Adolescents with Major Depressive Disorder. Journal of Child and Adolescent Psychopharmacology. 2023;33(10):418-427. doi:10.1089/cap.2023.0048
BibTeX
@article{Saito2023,
author = {Saito, Takuya and Takahashi, Hidetoshi and Tsujii, Noa and Sasaki, Tsuyoshi and Yamaguchi, Yuta and Takatsu, Masahiro and Sato, Masaki},
title = {Efficacy of Preventing Relapse Evaluated by a Multicenter Randomized Double-Blind Placebo-Controlled Withdrawal Study of Escitalopram in Japanese Adolescents with Major Depressive Disorder},
journal = {Journal of Child and Adolescent Psychopharmacology},
year = {2023},
volume = {33},
number = {10},
pages = {418--427},
doi = {10.1089/cap.2023.0048}
}
EUVIMED